What the FDA labels say about taking them together
Dihydroergotamine and sumatriptan
Dihydroergotamine's FDA label of March 6, 2025 names sumatriptan in its contraindications section, and sumatriptan's label names dihydroergotamine too. The sumatriptan label: “Because these effects may be additive, use of ergotamine-containing or ergot-type medications and IMITREX tablets within 24 hours of each other is contraindicated.”
Check it at the source: the dihydroergotamine FDA label on DailyMed (effective March 6, 2025, Oceanside Pharmaceuticals); the sumatriptan FDA label on DailyMed (effective May 12, 2026, Aurobindo Pharma Limited).
What does the dihydroergotamine label say about sumatriptan?
Dihydroergotamine label, contraindicationsDihydroergotamine Mesylate Nasal Spray, 5-HT 1 agonists (e.g., sumatriptan), ergotamine-containing or ergot-type medications or methysergide should not be used within 24 hours of each other.
Dihydroergotamine label, drug interactionsSumatriptan and Dihydroergotamine Mesylate Nasal Spray should not be taken within 24 hours of each other ( see CONTRAINDICATIONS ).
Trudhesa label (Impel Pharmaceuticals LLC, September 3, 2026), contraindications… arterial disease with sepsis following vascular surgery with severe hepatic impairment with severe renal impairment with known hypersensitivity to ergot alkaloids with recent use (i.e., within 24 hours) of other 5-HT 1 agonists (e.g., sumatriptan) or ergotamine-containing or ergot-type medications [see Drug Interactions (7.2) ] with concomitant use of peripheral and central vasoconstrictors because the combination may result in additive or synergistic elevation of blood pressure [see Warnings and Precautions (5.5) ] Concomitant use of strong CYP3A4 inhibitors ( 4 ) Patients with ischemic heart disease or coronary artery vasospasm ( 4 ) Patients with uncontrolled hypertension, peripheral …
Source: FDA drug label (Trudhesa, NDA213436), Impel Pharmaceuticals LLC, effective September 3, 2026 (SPL set b81397b0-910d-4eb4-8fee-a9a3c9d94d63), via openFDA
Source: FDA drug label (Dihydroergotamine Mesylate), NDA020148 (Bausch), as published by Oceanside Pharmaceuticals, effective March 6, 2025 (SPL set 977de209-c53a-4cb4-9f3f-1e850600a9dc), via openFDA; the full label on DailyMed
What does the sumatriptan label say about dihydroergotamine?
Sumatriptan label, contraindications… (5.5) ] Ischemic bowel disease [see Warnings and Precautions (5.5) ] Uncontrolled hypertension [see Warnings and Precautions (5.8) ] Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine 1 (5-HT 1 ) agonist [see Drug Interactions (7.1, 7.3) ] Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor [see Drug Interactions (7.2), Clinical Pharmacology (12.3) ] Hypersensitivity to sumatriptan tablets (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9) ] Severe hepatic impairment [see Use in Specific …
Sumatriptan label, drug interactionsBecause these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan tablets within 24 hours of each other is contraindicated.
Imitrex label (GlaxoSmithKline LLC, December 9, 2025), contraindicationsRecent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine 1 (5-HT 1 ) agonist [see Drug Interactions (7.1, 7.3)]
Source: FDA drug label (Imitrex, NDA020132), GlaxoSmithKline LLC, effective December 9, 2025 (SPL set 584abe73-8290-4484-ff8e-5890831c095e), via openFDA
Source: FDA drug label (Sumatriptan), Aurobindo Pharma Limited, effective May 12, 2026 (SPL set b2503fff-c978-4efa-b1b4-d7740b6b26f2), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dihydroergotamine | Sumatriptan | |
|---|---|---|
| Labeled for | Migraine | Migraine |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $29.44 per mL 4 mg/mL nasal spray | $0.302 per tablet 50 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once